Sharon Alroy-Preis
#114,424
Most Influential Person Now
Israeli epidemiologist
Sharon Alroy-Preis's AcademicInfluence.com Rankings
Sharon Alroy-Preismedical Degrees
Medical
#2270
World Rank
#2680
Historical Rank
Epidemiology
#854
World Rank
#890
Historical Rank

Download Badge
Medical
Sharon Alroy-Preis's Degrees
- Bachelors Biology Tel Aviv University
Similar Degrees You Can Earn
Why Is Sharon Alroy-Preis Influential?
(Suggest an Edit or Addition)According to Wikipedia, Sharon Alroy-Preis is the head of public health services at the Israeli Health Ministry, and is Israel's chief epidemiologist. Education Alroy-Preis holds a doctorate in medicine from the Technion and a master's degree from the Dartmouth Institute for Health Policy and Clinical Practice .
Sharon Alroy-Preis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data (2021) (1074)
- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel (2021) (777)
- Waning Immunity after the BNT162b2 Vaccine in Israel (2021) (612)
- Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel (2021) (339)
- Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection (2021) (310)
- Protection by a Fourth Dose of BNT162b2 against Omicron in Israel (2022) (175)
- Protection against Covid-19 by BNT162b2 Booster across Age Groups (2021) (133)
- Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 (2022) (132)
- Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel (2021) (117)
- Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel (2021) (104)
- Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 (2021) (66)
- Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study (2021) (62)
- Protection and waning of natural and hybrid COVID-19 immunity (2021) (43)
- Myocarditis after BNT162b2 Vaccination in Israeli Adolescents (2022) (39)
- BNT162b2 vaccine booster dose protection: A nationwide study from Israel (2021) (31)
- Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel (2021) (30)
- Performance of the OraQuick HCV Rapid Antibody Test for Screening Exposed Patients in a Hepatitis C Outbreak Investigation (2014) (25)
- Protection by 4th dose of BNT162b2 against Omicron in Israel (2022) (23)
- COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022 (2022) (18)
- Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19 (2021) (17)
- Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study (2021) (14)
- Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician (2018) (12)
- BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals (2021) (11)
- Multistate fungal meningitis outbreak -- interim guidance for treatment. (2012) (10)
- The Israeli Experience with the “Green Pass” Policy Highlights Issues to Be Considered by Policymakers in Other Countries (2021) (9)
- The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021 (2021) (9)
- Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study (2022) (6)
- Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine (2022) (6)
- Emergence of genetically linked vaccine-originated poliovirus type 2 in the absence of oral polio vaccine, Jerusalem, April to July 2022 (2022) (5)
- Exposure to nitrogen dioxide in an indoor ice arena - New Hampshire, 2011. (2012) (5)
- Initial protection against Omicron in children and adolescents by BNT162b2 (2022) (3)
- BNT162b2 Vaccination Efficacy is Marginally Affected by the SARS-CoV-2 B.1.351 Variant in Fully Vaccinated Individuals (2021) (2)
- Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel (2021) (2)
- Myocarditis After BNT162b2 COVID-19 Third Booster Vaccine in Israel (2022) (2)
- Taken to Court: Defending Public Health Authority to Access Medical Records during an Outbreak Investigation (2015) (1)
- Environmental surveillance detected type 3 vaccine-derived polioviruses in increasing frequency at multiple sites prior to detection of a poliomyelitis case. (2023) (1)
- Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study (2023) (1)
- Protection against omicron severe disease 0-7 months after BNT162b2 booster (2022) (1)
- How compassionate use enabled Israel to deliver the Pfizer‐BioNTech COVID‐19 vaccination to vulnerable children aged 12–15 years before regulatory approval (2021) (1)
- International Society for Disease Surveillance Conference 2011: Building the Future of Public Health Surveillance (2011) (1)
- Pseudomonas Infections: Do we really need double coverage? A Systematic Review (2009) (0)
- Correlates of Protection of BNT162b2 Against COVID-19 Infection and Intensity of Symptomatic Disease; the Israeli COVID-19 Family Study (ICoFS) (2022) (0)
- Variation in the Timing of Administration of First Dose of Antibiotics - Do We Know What “Timely” Means? (2009) (0)
- Hepatitis C Outbreak in New Hampshire Due to Narcotic Diversion by a Healthcare Worker: The Detective Role of Public Health (2013) (0)
- School absenteeism surveillance data during the 2009 influenza A/H1N1 pandemic (2011) (0)
- Protection following BNT162b2 booster substantially exceeds that of a fresh 2-dose vaccine: a quasi-experimental study (2021) (0)
- Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster (2023) (0)
- New Hamphire Health Wisdom: Providing Customized Population Health Data to Improve Population Health (2013) (0)
This paper list is powered by the following services:
Other Resources About Sharon Alroy-Preis
What Schools Are Affiliated With Sharon Alroy-Preis?
Sharon Alroy-Preis is affiliated with the following schools: